Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease Therapy
New Alzheimer disease therapy research reported from King's College London, Pharmaceutical Sciences Research Division
July 10th, 2007
A new study, "A copper-binding site in the cytoplasmic domain of BACE1 identifies a possible link to metal homoeostasis and oxidative stress in Alzheimer's disease," is now available. According to a study from London, the United Kingdom, "The amyloidogenic processing pathway of the APP (amyloid precursor protein) generates Abeta (amyloid beta-peptide), the major constituent in Alzheimer's disease senile plaques. This processing is catalysed by two unusual membrane-localized aspartic proteinases, beta-secretase [BACE1 (beta-site APP-cleaving enzyme 1)] and the gamma-secretase complex." "There is a clear link between APP processing and copper homoeostasis in the brain....
Source: Drug Law Weekly (2007-07-10)
|
